Company description

CYTH, also known as Cyclacel Pharmaceuticals, Inc., is a biopharmaceutical company that specializes in the development and commercialization of innovative cancer therapies. Founded in 1996, the company is headquartered in Berkeley Heights, New Jersey and has a strong focus on advancing science to improve the lives of patients. CYTH has a proprietary pipeline of small molecule drugs targeting various types of cancer, including those with unmet medical needs. The company's lead product candidate, sapacitabine, is currently in advanced clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). CYTH also has a strategic collaboration with the University of Texas MD Anderson Cancer Center to evaluate combination therapies for patients with AML. In addition to its core data-driven approach to drug development, CYTH also prioritizes building relationships with key opinion leaders and strategic partnerships with other leading pharmaceutical companies. With a dedicated team of experienced scientists and executives, CYTH is committed to driving success in the oncology field and making a positive impact on patients worldwide.